The Financial Footprint of a Specialty Patient

Einodshofer explains how the costs associated with one specialty patient's treatment can have the same financial footprint as an entire population of patients. Video from PBMI's Drug Benefit Conference 2013.

Einodshofer explains how the costs associated with one specialty patient's treatment can have the same financial footprint as an entire population of patients. Video from PBMI's Drug Benefit Conference 2013.

Related Videos
View All
Related Content

MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal Cancer

January 27th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Phase 3 Trial Showed Zolbetuximab Significantly Improved Survival In Patients with Metastatic Gastric, Gastroesophageal Cancers

January 26th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

HIV Antiviral Therapies May Have Different Metabolic Signature

January 23rd 2023

FDA Grants Rare Pediatric Disease Designation to OR-440 for Treatment of Adrenocortical Carcinoma

January 23rd 2023

MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal Cancer

January 27th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Phase 3 Trial Showed Zolbetuximab Significantly Improved Survival In Patients with Metastatic Gastric, Gastroesophageal Cancers

January 26th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

HIV Antiviral Therapies May Have Different Metabolic Signature

January 23rd 2023

FDA Grants Rare Pediatric Disease Designation to OR-440 for Treatment of Adrenocortical Carcinoma

January 23rd 2023

MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal Cancer

January 27th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Phase 3 Trial Showed Zolbetuximab Significantly Improved Survival In Patients with Metastatic Gastric, Gastroesophageal Cancers

January 26th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

HIV Antiviral Therapies May Have Different Metabolic Signature

January 23rd 2023

FDA Grants Rare Pediatric Disease Designation to OR-440 for Treatment of Adrenocortical Carcinoma

January 23rd 2023
About Us
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.